• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI Executive AssistantNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Helper
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees for your businessNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Tilray Brands Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

    7/28/25 4:32:41 PM ET
    $TLRY
    Medicinal Chemicals and Botanical Products
    Health Care
    Get the next $TLRY alert in real time by email
    Form 8-K
    False000173134800017313482025-07-282025-07-28iso4217:USDxbrli:sharesiso4217:USDxbrli:shares
     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

    _________________

    FORM 8-K

    _________________

    CURRENT REPORT

    Pursuant to Section 13 or 15(d)
    of the Securities Exchange Act of 1934

    Date of Report (Date of earliest event reported):  July 28, 2025

    _______________________________

    Tilray Brands, Inc.

    (Exact name of registrant as specified in its charter)

    _______________________________

    Delaware001-3859482-4310622
    (State or Other Jurisdiction of Incorporation)(Commission File Number)(I.R.S. Employer Identification No.)

    265 Talbot Street West

    Leamington, Ontario N8H 4H3

    (Address of Principal Executive Offices) (Zip Code)

    (844) 845-7291

    (Registrant's telephone number, including area code)

    Not Applicable

    (Former name or former address, if changed since last report)

    _______________________________

    Check the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under any of the following provisions:

    ☐Written communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)
    ☐Soliciting material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)
    ☐Pre-commencement communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))
    ☐Pre-commencement communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e-4(c))

    Securities registered pursuant to Section 12(b) of the Act:

    Title of each classTrading Symbol(s)Name of each exchange on which registered
    Common stock, par value $0.0001 per shareTLRYThe NASDAQ Global Select Market

    Indicate by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (§230.405 of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (§240.12b-2 of this chapter).

    Emerging growth company ☐

    If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☐

     
     
    Item 2.02. Results of Operations and Financial Condition.

     

    On July 28, 2025, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

     

    Item 9.01. Financial Statements and Exhibits.

     

    (d) Exhibits

     

    Exhibit Number Description
       
    99.1 Press Release dated July 28, 2025
    104 Cover Page Interactive Data File (embedded within the Inline XBRL document)
     
     

     

    SIGNATURE

     

    Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized.

     

     Tilray Brands, Inc.
       
      
    Date: July 28, 2025By: /s/ Mitchell Gendel        
      Mitchell Gendel
      Global General Counsel
      

     

    Get the next $TLRY alert in real time by email

    Crush Q3 2025 with the Best AI Executive Assistant

    Stay ahead of the competition with Tailforce.ai - your AI-powered business intelligence partner.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Tailforce.ai

    Recent Analyst Ratings for
    $TLRY

    DatePrice TargetRatingAnalyst
    4/5/2024$2.25 → $2.75Neutral
    Alliance Global Partners
    11/2/2022$3.90Mkt Perform
    Bernstein
    7/29/2022$3.00Hold → Sell
    The Benchmark Company
    3/4/2022$9.00Hold → Buy
    Canaccord Genuity
    1/11/2022$7.40 → $6.90Neutral
    Cantor Fitzgerald
    1/7/2022$11.80 → $7.40Neutral
    Cantor Fitzgerald
    11/18/2021$10.00Underweight
    Barclays
    11/1/2021$18.00 → $11.80Overweight → Neutral
    Cantor Fitzgerald
    More analyst ratings

    $TLRY
    SEC Filings

    See more
    • SEC Form 10-K filed by Tilray Brands Inc.

      10-K - Tilray Brands, Inc. (0001731348) (Filer)

      7/28/25 7:22:54 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Tilray Brands Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits

      8-K - Tilray Brands, Inc. (0001731348) (Filer)

      7/28/25 4:32:41 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Tilray Brands Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities

      8-K - Tilray Brands, Inc. (0001731348) (Filer)

      6/23/25 4:10:42 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care

    $TLRY
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Simon Irwin D bought $100,106 worth of shares (165,000 units at $0.61), increasing direct ownership by 4% to 3,941,633 units (SEC Form 4)

      4 - Tilray Brands, Inc. (0001731348) (Issuer)

      7/30/25 6:52:32 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Financial Officer Merton Carl A bought $19,939 worth of shares (33,500 units at $0.60), increasing direct ownership by 4% to 798,069 units (SEC Form 4)

      4 - Tilray Brands, Inc. (0001731348) (Issuer)

      7/30/25 3:12:46 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • President and CEO Simon Irwin D exercised 1,178,109 shares at a strike of $0.41 and covered exercise/tax liability with 647,960 shares, increasing direct ownership by 16% to 3,776,633 units (SEC Form 4)

      4 - Tilray Brands, Inc. (0001731348) (Issuer)

      6/4/25 5:01:34 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care

    $TLRY
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Alliance Global Partners reiterated coverage on Tilray with a new price target

      Alliance Global Partners reiterated coverage of Tilray with a rating of Neutral and set a new price target of $2.75 from $2.25 previously

      4/5/24 7:39:50 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Bernstein initiated coverage on Tilray with a new price target

      Bernstein initiated coverage of Tilray with a rating of Mkt Perform and set a new price target of $3.90

      11/2/22 6:37:00 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Tilray downgraded by The Benchmark Company with a new price target

      The Benchmark Company downgraded Tilray from Hold to Sell and set a new price target of $3.00

      7/29/22 7:19:40 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care

    $TLRY
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Tilray Brands Reports Fourth Quarter and Fiscal 2025 Financial Results

      Fiscal Year Net Revenue of $821 Million, $834 Million in Constant Currency, Strategic Decisions Impacted Revenue by $35 Million Q4 Consolidated Adjusted EBITDA is the 2nd Highest in the Company's History International Cannabis Revenue Increased 71% in Q4 and 19% for the Fiscal Year; Canadian Cannabis Remained #1 by Revenue in the Fiscal Year; Global Cannabis Gross Margin Increased by ~700 Basis Points in the Fiscal Year 19% Revenue Growth in Tilray Beverages with $241 Million for the Fiscal Year 9% Revenue Growth in Tilray Wellness with $60 Million for the Fiscal Year Strong Balance Sheet with $256 Million Available in Cash and Marketable Securities; Total Debt Repayments of ~$100 Milli

      7/28/25 4:30:13 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Award-Winning Breckenridge Distillery Makes Bold Entry into Tequila with Launch of Casa Breck

      BRECKENRIDGE, Colo., July 24, 2025 (GLOBE NEWSWIRE) -- Breckenridge Distillery, an award-winning craft distillery and spirits brand by Tilray Brands, Inc. (NASDAQ:TLRY, TSX:TLRY), proudly celebrates International Tequila Day with the launch of Casa Breck Tequila - a bold leap into a new spirits category. Crafted with reverence for tradition and inspired by cross-cultural storytelling, Casa Breck represents a striking fusion of the Rocky Mountains' rugged spirit and the vibrant heart of Jalisco, Mexico. Photo Courtesy: Breckenridge Distillery Casa Breck Blanco and Casa Breck Reposado are the first offerings in this new line, each one a tribute to the time-honored craftsmanship of

      7/24/25 7:00:00 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Breckenridge Distillery Launches Mock One: Bold, Premium Non-Alcoholic Alternatives to Whiskey, Tequila, Gin & Rum - Crafted for Everyone Who Loves a Great Drink

      BRECKENRIDGE, Colo., July 17, 2025 (GLOBE NEWSWIRE) -- Breckenridge Distillery, an award-winning craft distillery and spirits brand by Tilray Brands, Inc. (NASDAQ:TLRY, TSX:TLRY), is pleased to announce the launch of Mock One, a new line of non-alcoholic spirits. Mock One is not just another non-alcoholic spirit - it's crafted by the team behind one of the most awarded craft distilleries in the United States. Backed by the expertise of the renowned Breckenridge Distillery, recipient of nine Icons of Whisky awards for excellence in quality, innovation, branding, and taste, Mock One brings the same uncompromising standards to the zero-proof category with spirit alternatives inspired by their

      7/17/25 7:00:00 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care

    $TLRY
    Insider Purchases

    Insider purchases reveal critical bullish sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President and CEO Simon Irwin D bought $100,106 worth of shares (165,000 units at $0.61), increasing direct ownership by 4% to 3,941,633 units (SEC Form 4)

      4 - Tilray Brands, Inc. (0001731348) (Issuer)

      7/30/25 6:52:32 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Financial Officer Merton Carl A bought $19,939 worth of shares (33,500 units at $0.60), increasing direct ownership by 4% to 798,069 units (SEC Form 4)

      4 - Tilray Brands, Inc. (0001731348) (Issuer)

      7/30/25 3:12:46 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Chief Financial Officer Merton Carl A bought $35,360 worth of shares (26,000 units at $1.36) (SEC Form 4)

      4 - Tilray Brands, Inc. (0001731348) (Issuer)

      11/18/24 11:29:05 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care

    $TLRY
    Leadership Updates

    Live Leadership Updates

    See more
    • Terrapin Beer Co. Celebrates 20 Years of Iconic Wake-n-Bake Beer with Exciting Wake-n-Bake Off Event in Athens, GA

      ATHENS, Ga., Jan. 23, 2025 (GLOBE NEWSWIRE) -- Terrapin Beer Co., a Tilray Beverages craft beer brand under Tilray Brands, Inc. (NASDAQ:TLRY, TSX:TLRY), is excited to announce the 20th anniversary of its Wake-n-Bake Coffee Oatmeal Imperial Stout seasonal beer and the annual Wake-n-Bake Off event on Sunday, January 26th, 2025, at the Terrapin taproom in Athens, GA. In celebration of its 20th anniversary, guests will have the chance to observe local restaurants competing to craft the finest dish featuring Terrapin's renowned Wake-n-Bake Beer. This event highlights culinary innovation and fosters community engagement through an array of sweet and savory tastings that showcase the rich flavor

      1/23/25 7:00:00 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Blue Point Brewing Launches Big Mo Brew to Raise Funds and Awareness for Men's Health During Movember

      PATCHOGUE, N.Y., Oct. 22, 2024 (GLOBE NEWSWIRE) -- Blue Point Brewing Company, Long Island's original craft brewery and subsidiary of Tilray Brands, (NASDAQ:TLRY, TSX:TLRY), is proud to announce the continuation of its men's health awareness campaign in support of Movember. The month shines a light on key men's health issues—mental health, prostate cancer, and testicular cancer—encouraging open conversations and proactive engagement. To honor the initiative, Blue Point Brewing announced the special release of its classic double IPA, Big Mo, available at our brewery and retailers in Long Island, New York. This hazy double IPA, featuring prominent mosaic hops and an ABV of 8.0%, proud

      10/22/24 7:00:00 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Breckenridge Brewery Opens New Location in Fort Collins, Colorado

      FORT COLLINS, Colo., Aug. 05, 2024 (GLOBE NEWSWIRE) -- Breckenridge Brewery, a Colorado-based craft brewer with over 30 years of experience brewing approachable, well-balanced beers, announces the opening of its new brewery location in Fort Collins. With doors opening in early August 2024, the new 10,000-square-foot Breckenridge Brewery offers a full restaurant experience and a new vibrant atmosphere in the heart of Fort Collins for all to enjoy. The new location will be a full-service restaurant, upholding the Breckenridge Brewery legacy while ushering in new opportunities for innovation and community collaboration. With a menu boasting a diverse range of culinary delights designed to co

      8/5/24 7:00:00 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care

    $TLRY
    Financials

    Live finance-specific insights

    See more
    • Tilray Brands Reports Fourth Quarter and Fiscal 2025 Financial Results

      Fiscal Year Net Revenue of $821 Million, $834 Million in Constant Currency, Strategic Decisions Impacted Revenue by $35 Million Q4 Consolidated Adjusted EBITDA is the 2nd Highest in the Company's History International Cannabis Revenue Increased 71% in Q4 and 19% for the Fiscal Year; Canadian Cannabis Remained #1 by Revenue in the Fiscal Year; Global Cannabis Gross Margin Increased by ~700 Basis Points in the Fiscal Year 19% Revenue Growth in Tilray Beverages with $241 Million for the Fiscal Year 9% Revenue Growth in Tilray Wellness with $60 Million for the Fiscal Year Strong Balance Sheet with $256 Million Available in Cash and Marketable Securities; Total Debt Repayments of ~$100 Milli

      7/28/25 4:30:13 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Tilray Brands to Announce Fourth Quarter and Fiscal Year 2025 Financial Results on July 28, 2025

      NEW YORK and LEAMINGTON, Ontario, July 09, 2025 (GLOBE NEWSWIRE) -- Tilray Brands, Inc. ("Tilray" or the "Company") (NASDAQ:TLRY, TSX:TLRY), a global lifestyle and consumer packaged goods company at the forefront of the beverage, cannabis and wellness industries, today announced that the Company will release its financial results for the fourth quarter and full fiscal year ended May 31, 2025, after market close on Monday, July 28, 2025. Live Conference Call and Audio Webcast Tilray will host a live conference call, which will be webcast, to discuss these results at 4:30 PM Eastern Time. The webcast can be accessed on the Events & Presentations section of Tilray's Investor Relations websi

      7/9/25 7:00:00 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • Tilray Brands Reports Q3 Fiscal 2025 Financial Results

      Tilray Confirms No Current Impact of Tariffs Generated Net Revenue of $186 Million in the Third Quarter, $193 Million in Constant Currency; Strategic Initiatives and SKU Rationalization Impacted Revenue by $13 Million Tilray Beverage Expands U.S. Distribution of Hemp-Derived THC Drinks Across 10 States, Increases Project 420 Cost Savings Plan to $33 Million Tilray Cannabis Increased Gross Margins by 800 bps, Remains the Leader in Canada by Sales Performance, and Generates Strong Sales Growth in Germany Strengthens Balance Sheet with Convertible Note Reduction of $58 Million and Total Debt Reduction of $71 Million, $248 Million Available in Cash and Marketable Securities NEW Y

      4/8/25 7:00:00 AM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care

    $TLRY
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • SEC Form SC 13G/A filed by Tilray Brands Inc. (Amendment)

      SC 13G/A - Tilray Brands, Inc. (0001731348) (Subject)

      2/13/23 1:34:44 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13G filed by Tilray Brands Inc.

      SC 13G - Tilray Brands, Inc. (0001731348) (Subject)

      2/10/23 4:41:36 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care
    • SEC Form SC 13D filed by Tilray Brands Inc.

      SC 13D - Tilray Brands, Inc. (0001731348) (Filed by)

      7/22/22 4:30:22 PM ET
      $TLRY
      Medicinal Chemicals and Botanical Products
      Health Care